Radionetics Oncology
Greg Reinhart is currently working as the Principal Scientist at Radionetics Oncology, focusing on in vitro pharmacology. With previous experience as a Senior Scientist at Crinetics Pharmaceuticals and Scientist I at Receptos, Inc., as well as a background in molecular biology and assay development, Greg has a strong foundation in drug discovery and program support. They possess a Bachelor's degree in General Biology from San Diego State University.
Radionetics Oncology
Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company’s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.